|
Evaluation of clonal hematopoiesis in late stage NSCLC using a next-generation sequencing panel targeting cancer genes. |
|
|
|
Patents, Royalties, Other Intellectual Property - Patent filed on precise microbiota engineering, Harvard University; Various patents filed on tumor heterogeneity and other biomarkers predicting response to therapy, Roche Sequencing Solutions |
|
|
Employment - Signature Diagnostics |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Novartis |
Patents, Royalties, Other Intellectual Property - Patent filed on Tumor Heterogeneity from Liquid Biopsy Roche Sequencing Solutions |
|
|
|
|
|
|
Stock and Other Ownership Interests - roche |
|
Travel, Accommodations, Expenses - roche |
|
|
|
Stock and Other Ownership Interests - Clovis Oncology; Editas Medicine; Exact Sciences; Johnson & Johnson; Roche |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Roche |
Travel, Accommodations, Expenses - Roche |